IP Library Granted Patent US 7,256,310
Granted Patent B2
US 7,256,310 · App. 10/728,873 · Granted Aug 14, 2007

Levalbuterol salt

Assignee: Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,256,310
App. No.
10/728,873
Granted
Aug 14, 2007
Kind
B2
Abstract

Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.

Claims (29)

1. Levalbuterol L-tartrate.

2. Levalbuterol L-tartrate as claimed in claim 1 , which is in crystalline form.

3. Levalbuterol L-tartrate as claimed in claim 2 , containing from 0.3 to 0.7% ethanol.

4. Levalbuterol L-tartrate as claimed in claim 2 , which is in micronized form.

5. Levalbuterol L-tartrate as claimed in claim 4 , which is in the form of needle-like particles.

6. A pharmaceutical composition, which comprises levalbuterol L-tartrate as claimed in claim 1 , together with a pharmaceutically acceptable carrier.

7. A pharmaceutical composition as claimed in claim 6 , which is an aerosol formulation adapted for administration using a metered dose inhaler, the aerosol formulation comprising levalbuterol L-tartrate in crystalline form and a propellant.

8. A pharmaceutical composition as claimed in claim 7 , in which the propellant is 1,1,1,2-tetrafluoroethane.

9. A pharmaceutical composition as claimed in claim 7 , which further comprises a surfactant.

10. A pharmaceutical composition as claimed in claim 7 , which further comprises a co-solvent.

11. A pharmaceutical composition as claimed in claim 10 , in which the co-solvent is ethanol.

12. An aerosol formulation adapted for administration using a metered dose inhaler, the aerosol formulation comprising levalbuterol L-tartrate crystals in the form of micronized, needle-like particles, and a propellant.

13. An aerosol formulation as claimed in claim 12 , in which the propellant is 1,1,1,2-tetrafluoroethane.

14. An aerosol formulation as claimed in claim 13 , which further comprises from 2 to 6% by weight of ethanol as a co-solvent.

15. A metered dose inhaler comprising a canister containing an aerosol formulation as defined in claim 7 , a metering valve and a valve stem.

16. A metered dose inhaler comprising a canister containing an aerosol formulation as defined in claim 12 , a metering valve and a valve stem.

17. A pharmaceutical composition as claimed in claim 6 , which is adapted for administration using a dry powder inhaler or insufflator.

18. A process for the preparation of levalbuterol L-tartrate crystals, which comprises combining a solution of levalbuterol with a solution of L-tartaric acid and recovering levalbuterol L-tartrate crystals.

19. A process as claimed in claim 18 , in which the solvent in each solution comprises ethanol.

20. A process as claimed in claim 18 , in which the crystallization conditions are selected so as to provide crystals having a length of 10 to 50 microns and a width of 0.2 to 4 microns.

21. A process as claimed in claim 18 , in which the levalbuterol has been prepared by hydrogenating R-benzylalbuterol in the presence of palladium on carbon.

22. A process as claimed in claim 21 , in which the hydrogenation has been conducted under conditions selected to effect conversion of at least 99.9% of the R-benzylalbuterol without over reduction of other functional groups.

23. A process as claimed in claim 18 , in which the crystals are dried and micronized, the crystallization and drying conditions being selected so as to afford needle-like particles after micronization.

24. A process for the preparation of levalbuterol L-tartrate crystals, which comprises combining a solution of levalbuterol with a solution of L-tartaric acid, recovering levalbuterol L-tartrate crystals, and then drying and micronizing the recovered crystals, the crystallization and drying conditions being selected so as to afford needle-like particles after micronization.

25. Levalbuterol L-tartrate crystals obtained by the process of claim 18 .

26. Levalbuterol L-tartrate crystals obtained by the process of claim 24 .

27. A method of effecting bronchodilation in a patient in need of treatment, which comprises administering to said patient an effective amount of levalbuterol L-tartrate.

28. A method as claimed in claim 27 , in which micronized crystals of levalbuterol L-tartrate are administered by inhalation using a metered dose inhaler.

29. A method as claimed in claim 28 , in which the micronized crystals of levalbuterol L-tartrate are in the form of needle-like particles.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2023
From: SUNOVION PHARMACEUTICALS INC.
To: LUPIN INC.
Reel/Frame 062636/0023 →
CHANGE OF NAME Recorded Dec 9, 2010
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025484/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: STURGE, CRAIG
To: SEPRACOR, INC.
Reel/Frame 014776/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: BAKALE, ROGER
To: SEPRACOR INC.
Reel/Frame 014776/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: MCGLYNN, PAUL
To: SEPRACOR INC.
Reel/Frame 014776/0812 →
Continuity (2)
Provisional Application 6043219500 · Dec 10, 2002
Related Publication 20040115136A1 · Jun 17, 2004